Pharmacokinetics of droloxifene and its metabolites in breast cancer patients.
Pharmacokinetics and metabolism of droloxifene, a new antiestrogenic drug, have been investigated by single- and multiple-dose studies in postmenopausal patients with advanced breast cancer. Short terminal elimination half-life, low accumulation, and improved drug tolerability are the most striking features of this safe and effective new antiestrogen. Bioequivalence of film-coated tablet, tablet, and standard solution of droloxifene has been shown. The concentrations of droloxifene and its metabolites have been determined by a highly selective HPLC method.
Grill
H J
HJ
Abteilung für Experimentelle Endokrinologie, Klinikum der Johannes Gutenberg Universität, Mainz, Germany.
Pollow
K
K
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000378:metabolism / Q000493:pharmacokinetics*; D001682:Biological Availability; D001943:Breast Neoplasms / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid; D004341:Drug Evaluation; D004965:Estrogen Antagonists / Q000378:metabolism / Q000493:pharmacokinetics*; D005260:Female; D006207:Half-Life; D006801:Humans; D008875:Middle Aged; D013629:Tamoxifen / Q000031:analogs & derivatives* / Q000378:metabolism / Q000493:pharmacokinetics
D000970:Antineoplastic Agents; D004965:Estrogen Antagonists; D013629:Tamoxifen; C038345:droloxifene